All In Biotech

Drug Trial Radar · NCT07650916

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 564 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

564

Planned (sponsor's estimate)

Start

Jun 25, 2026

Primary completion

Aug 13, 2029

Study completion Aug 13, 2029

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Jun 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).

Conditions

  • HIV

Interventions

  • CAB ULADrug

    CAB ULA will be administered.

  • RPV ULADrug

    RPV ULA will be administered.

  • CAB LADrug

    CAB LA will be administered.

  • RPV LADrug

    RPV LA will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with plasma HIV-RNA greater than or equal to (>=) 50 copies (c)/mL as per Food and Drug Administration (FDA) Snapshot algorithmTime frame: At Month 11

Locations

111 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona · Recruiting

  • GSK Investigational Site

    Bakersfield, California · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    San Diego, California · Recruiting

  • GSK Investigational Site

    West Hollywood, California · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • GSK Investigational Site

    DeLand, Florida · Recruiting

  • GSK Investigational Site

    Fort Lauderdale, Florida · Recruiting

  • GSK Investigational Site

    Ft. Pierce, Florida · Recruiting

  • GSK Investigational Site

    Jacksonville, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Orlando, Florida · Recruiting

  • GSK Investigational Site

    Pensacola, Florida · Recruiting

  • GSK Investigational Site

    Vero Beach, Florida · Recruiting

  • GSK Investigational Site

    West Palm Beach, Florida · Recruiting

  • GSK Investigational Site

    West Palm Beach, Florida · Recruiting

  • GSK Investigational Site

    Decatur, Georgia · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    Baltimore, Maryland · Recruiting

  • GSK Investigational Site

    Grosse Pointe Woods, Michigan · Recruiting

  • GSK Investigational Site

    Kansas City, Missouri · Recruiting

  • GSK Investigational Site

    Las Vegas, Nevada · Recruiting

  • GSK Investigational Site

    Newark, New Jersey · Recruiting

  • GSK Investigational Site

    Santa Fe, New Mexico · Recruiting

  • GSK Investigational Site

    Stony Brook, New York · Recruiting

  • GSK Investigational Site

    Syracuse, New York · Recruiting

  • GSK Investigational Site

    Greensboro, North Carolina · Recruiting

  • GSK Investigational Site

    Winston-Salem, North Carolina · Recruiting

  • GSK Investigational Site

    Columbus, Ohio · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    Pittsburgh, Pennsylvania · Recruiting

  • GSK Investigational Site

    Pittsburgh, Pennsylvania · Recruiting

  • GSK Investigational Site

    Memphis, Tennessee · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Recruiting

  • GSK Investigational Site

    El Paso, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.